Foram Parekh shares insights on CDMO companies’ positive outlook post-Covid correction, potential impact of Biosecure Law, concerns about Laurus’s earnings improvement, Sun Pharma’s specialty sales focus, and recommendations for pharma sector growth with Lupin and Dr Reddy’s.
Subscribe To Our Free Newsletter |